Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MACK Merrimack Pharmaceuticals (MACK) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisDividendEarningsHeadlinesInsider TradesOwnershipTrends About Merrimack Pharmaceuticals Stock (NASDAQ:MACK) 30 days 90 days 365 days Advanced Chart Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Get MACK alerts:Sign Up Key Stats Today's Range$15.13▼$15.1350-Day Range$14.65▼$15.1352-Week Range$11.53▼$15.89VolumeN/AAverage Volume396,929 shsMarket Capitalization$223.77 millionP/E Ratio1.09Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewMerrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.Read More… This Bull Market Indicator called NVDA at $116 (Ad)Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Receive MACK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address MACK Stock News HeadlinesCollege football connection: Easton’s Hutchison posts 2 TDs in F&M victorySeptember 25, 2024 | msn.comMACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q1 2024May 16, 2024 | investorplace.comDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.November 21, 2024 | DTI (Ad)Merrimack Pharmaceuticals Shareholders OK Dissolution PlanMay 10, 2024 | marketwatch.comMerrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common StockMay 10, 2024 | businesswire.comMerrimack Pharmaceuticals intends to declare $15.10 dividendMay 9, 2024 | msn.comMerrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of DissolutionMay 9, 2024 | finance.yahoo.comMerrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of DissolutionApril 30, 2024 | businesswire.comSee More Headlines MACK Stock Analysis - Frequently Asked Questions How were Merrimack Pharmaceuticals' earnings last quarter? Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced its earnings results on Friday, May, 10th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.14. When did Merrimack Pharmaceuticals' stock split? Merrimack Pharmaceuticals shares reverse split on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Merrimack Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Merrimack Pharmaceuticals investors own include Rite Aid (RAD), Agenus (AGEN), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Bristol-Myers Squibb (BMY) and Meta Platforms (META). Company Calendar Last Earnings5/10/2019Today11/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:MACK Previous SymbolNASDAQ:MACK CUSIP59032810 CIK1274792 Webwww.merrimackpharma.com Phone617-720-8606Fax617-491-1386Employees426Year Founded2000Profitability EPS (Most Recent Fiscal Year)$13.87 Trailing P/E Ratio1.09 Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,180,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-1.93% Return on Assets-1.78% Debt Debt-to-Equity RatioN/A Current Ratio10.78 Quick Ratio10.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.31 per share Price / Book11.55Miscellaneous Outstanding Shares14,790,000Free Float10,267,000Market Cap$223.77 million OptionableOptionable Beta1.45 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report This page (NASDAQ:MACK) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merrimack Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Merrimack Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
